Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics

Advances in Pulmonary Drug Delivery Systems and Inhalation Formulations

“…Conventional PK studies may not consider potential difference in lung performance between reference and generic inhalation products. Hochhaus et al [10] propose a population PK approach that could characterize the regional lung deposition by identifying and estimating the absorption of fluticasone propionate presumably from central and peripheral lung. Such approach could be useful to evaluate bioequivalence of inhalation products instead of clinical trials.…”